Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101 Administered Intravenously or Subcutaneously in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101 Administered Intravenously or Subcutaneously in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegrizeprument (Primary) ; Pegrizeprument (Primary)
  • Indications Transplant rejection
  • Focus Adverse reactions
  • Sponsors Veloxis Pharmaceuticals

    • Most Recent Events

    • 05 Jun 2024 According to Veloxis Pharmaceuticals, Inc media release, The company partner Veloxis presented positive results from this study in oral session at the American Transplant Congress 2024. and this results will facilitate dose selection in preparation for a Phase 2 study in kidney transplant recipients
    • 30 May 2024 According to Veloxis Pharmaceuticals, Inc media release, data from this trial will be presented at the 2024 American Transplant Congress (ATC). Taking place June 1-5 in Philadelphia, ATC is the joint annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 19 Jan 2024 According to an OSE Immunotherapeutics media release, results from this study expected in 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top